Virginia Home Care Services, Inc.

Virginiahcs.com

Virginia Home Care Services, Inc. Is a personal care agency that targets helping individuals that need assistance with personal hygiene, toileting, dressing, mobility, eating, light house keeping, and other daily errands.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

news image

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

news image

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More

SWISS BIOTECH RAISES €16M TO TREAT AUTISM SPECTRUM DISORDER

Labiotech | February 04, 2020

news image

Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not disclosed, but include European and US private equity investors. The Swiss company will use the money to progress its lead candidate treatment for autism spectrum disorder into a ph...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

BIOCYTOGEN LAUNCHES RENNANO™ MOUSE, A FULLY HUMAN HEAVY CHAIN ANTIBODY PLATFORM

Biocytogen | January 05, 2023

news image

RenNano™, a fully human heavy-chain antibody platform developed by Biocytogen Pharmaceuticals Co., Ltd., has been launched officially. RenNano™ joins RenMab™ and RenLite® as the newest member of the RenMice™ family. All three RenMice™ technologies from Biocytogen work together to speed up the search and development of entirely human monoclonal, bispecific/multispecific, and single-domain antibodies (sdAbs, or nanobodies). Camels and sharks produce...

Read More
news image

CELL AND GENE THERAPY

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More
news image

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More
news image

SWISS BIOTECH RAISES €16M TO TREAT AUTISM SPECTRUM DISORDER

Labiotech | February 04, 2020

Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not disclosed, but include European and US private equity investors. The Swiss company will use the money to progress its lead candidate treatment for autism spectrum disorder into a ph...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

BIOCYTOGEN LAUNCHES RENNANO™ MOUSE, A FULLY HUMAN HEAVY CHAIN ANTIBODY PLATFORM

Biocytogen | January 05, 2023

RenNano™, a fully human heavy-chain antibody platform developed by Biocytogen Pharmaceuticals Co., Ltd., has been launched officially. RenNano™ joins RenMab™ and RenLite® as the newest member of the RenMice™ family. All three RenMice™ technologies from Biocytogen work together to speed up the search and development of entirely human monoclonal, bispecific/multispecific, and single-domain antibodies (sdAbs, or nanobodies). Camels and sharks produce...

Read More

Resources

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Single-cell RNA Sequencing and Analysis

Video

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Characterization and identification of glucuronide metabolites

Whitepaper

resource image

MEDICAL, INDUSTRY OUTLOOK

Microfluidics: Big developments on thesmall scale

Whitepaper

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Single-cell RNA Sequencing and Analysis

Video

resource image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Characterization and identification of glucuronide metabolites

Whitepaper

resource image

MEDICAL, INDUSTRY OUTLOOK

Microfluidics: Big developments on thesmall scale

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us